Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 1.54 HKD Market Closed
Market Cap: 1.2B HKD
Have any thoughts about
Jacobio Pharmaceuticals Group Co Ltd?
Write Note

Jacobio Pharmaceuticals Group Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jacobio Pharmaceuticals Group Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Net Income (Common)
-ÂĄ359.1m
CAGR 3-Years
38%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Net Income (Common)
ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Net Income (Common)
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
No Stocks Found

Jacobio Pharmaceuticals Group Co Ltd
Glance View

Market Cap
1.2B HKD
Industry
Biotechnology

Jacobio Pharmaceuticals Group Co., Ltd. operates as an investment holding company which engages in research and development of new drugs. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-12-21. The firm is primarily responsible for the independent discovery and development of innovative tumor therapies. The firm's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The firm mainly conducts business within the domestic market.

Intrinsic Value
0.89 HKD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common)?
Net Income (Common)
-359.1m CNY

Based on the financial report for Dec 31, 2023, Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common) amounts to -359.1m CNY.

What is Jacobio Pharmaceuticals Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-19%

Over the last year, the Net Income (Common) growth was 3%. The average annual Net Income (Common) growth rates for Jacobio Pharmaceuticals Group Co Ltd have been 38% over the past three years , -19% over the past five years .

Back to Top